---
layout: post
title: "Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation To Treat Clostridioides difficile Infection Not Responsive to Standard Therapies; Guidance for Industry; Availability"
date: 2026-02-05 19:01:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-26000
original_published: 2022-11-29 00:00:00 +0000
significance: 8.00
---

# Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation To Treat Clostridioides difficile Infection Not Responsive to Standard Therapies; Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 29, 2022 00:00 UTC
**Document Number:** 2022-26000

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance entitled "Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies; Guidance for Industry." The guidance document informs members of the medical and scientific community and other interested persons notice that, at this time, we intend to exercise enforcement discretion with respect to the investigational new drug application (IND) requirements for the use of fecal microbiota for transplantation (FMT) to treat Clostridioides difficile (C. difficile) infection not responding to standard therapies under limited circumstances described in the guidance. The guidance announced in this notice finalizes the draft guidance entitled "Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies" dated March 2016, and supersedes the guidance entitled "Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies" dated July 2013.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/29/2022-26000/enforcement-policy-regarding-investigational-new-drug-requirements-for-use-of-fecal-microbiota-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-26000

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
